natgillin/translations-raw huggingface dataset:
The efficacy of aripiprazole was studied in paediatric subjects with Tourette’s disorder (aripiprazole: n=99, placebo: n=44) in a randomised, double-blind, placebo controlled, 8 week study using a fixed dose weight- based treatment group design over the dose range of 5 mg/day to 20 mg/day and a starting dose of 2 mg.
Učinkovitost aripiprazola je bila raziskana pri pediatrični populaciji s Tourettovo motnjo (aripiprazol: n = 99, placebo: n = 44) v 8-tedenski randomizirani, dvojno slepi, s placebom nadzorovani študiji, zasnovani z zdravljenimi skupinami, ki so prejemale nespremenjen odmerek glede na telesno maso posameznika v razponu od 5 mg/dan do 20 mg/dan, z začetnim odmerkom 2 mg.
The efficacy of Arzerra has been evaluated in two clinical studies (OMB110911 and OMB115991) in patients with previously untreated CLL considered inappropriate for a fludarabine-based treatment, and two clinical studies (Hx-CD20-406 and Hx-CD20-402) in patients with relapsed or refractory CLL.
Učinkovitost zdravila Arzerra so ocenili v dveh kliničnih študijah (OMB110911 in OMB115991) pri bolnikih s predhodno nezdravljeno KLL, ki niso bili primerni za zdravljenje na podlagi fludarabina, in v dveh kliničnih študijah (Hx-CD20-406 in Hx-CD20-402) pri bolnikih z recidivno ali refraktarno KLL.
The efficacy of bazedoxifene was established in two multicentre, double-blind, randomised, placebo- and active-control, Phase 3 trials: 3-year osteoporosis treatment trial and a 2-year osteoporosis prevention trial.
Učinkovitost bazedoksifena so dokazali v dveh multicentričnih, dvojno slepih, randomiziranih, s placebom in drugo zdravilno učinkovino nadzorovanih preskušanjih 3. faze: 3-letno preskušanje zdravljenja osteoporoze in 2-letno preskušanje preprečevanja osteoporoze.
The efficacy of Benlysta was evaluated in 2 randomized, double-blind, placebo-controlled studies in 1,684 patients with a clinical diagnosis of SLE according to the American College of Rheumatology classification criteria.
Učinkovitost zdravila Benlysta so ocenili v 2 randomiziranih, dvojno slepih, s placebom kontroliranih študijah pri 1.684 bolnikih s klinično diagnozo SLE po klasifikacijskih merilih American College of Rheumatology.
The efficacy of Cerenia in reduction of nausea in cats was demonstrated in studies using a model (xylazine-induced nausea).
Učinkovitost zdravila Cerenia za zmanjšanje slabosti so dokazali v študijah z uporabo modela (navzea, inducirana z uporabo ksilazina).
The efficacy of Cerenia in reduction of nausea was demonstrated in studies using a model (xylazine- induced nausea).
Učinkovitost zdravila Cerenia za zmanjšanje slabosti so dokazali v študijah z uporabo modela (navzea, inducirana z uporabo ksilazina).
The efficacy of Cervarix was assessed in a double-blind, randomised Phase III clinical trial (HPV-015) that included a total of 5777 women aged 26 years and older.
Učinkovitost cepiva Cervarix so ocenili v dvojno slepi, randomizirani klinični študiji III. faze (HPV-015), ki je zajela skupno 5.777 žensk, starih 26 let in več.
The efficacy of Cervarix was assessed in two controlled, double-blind, randomised Phase II and III clinical trials that included a total of 19,778 women aged 15 to 25 years.
Učinkovitost cepiva Cervarix je bila ovrednotena v dveh nadzorovanih, dvojno slepih, randomiziranih kliničnih študijah II. in III. faze, v kateri je bilo skupaj vključenih 19.778 žensk, starih od 15 do 25 let.
The efficacy of clopidogrel was observed independently of the dose of ASA (75-325 mg once daily).
Učinkovitost klopidogrela je bila neodvisna od odmerka ASA (75–325 mg enkrat na dan).
The efficacy of COCs may be reduced in the event of e.g., missed tablets (see section 4.2), gastro- intestinal disturbances during active tablet-taking (see section 4.2) or use of concomitant medicinal products (see section 4.5).
Učinkovitost KPK je lahko zmanjšana v primeru npr. pozabljenih tablet (glejte poglavje 4.2), prebavnih težav med jemanjem tablet z zdravilno učinkovino (glejte poglavje 4.2) ali sočasne uporabe drugih zdravil (glejte poglavje 4.5).
The efficacy of COCs may be reduced in the event of e.g., missed tablets (see section 4.2), gastro-intestinal disturbances during active tablet-taking (see section 4.2) or use of concomitant medicinal products (see section 4.5).
Učinkovitost COC je lahko zmanjšana v primeru npr. pozabljenih tablet (glejte poglavje 4.2), prebavnih težav med jemanjem tablet z zdravilno učinkovino (glejte poglavje 4.2) ali sočasne uporabe drugih zdravil (glejte poglavje 4.5).
The efficacy of dabrafenib in the treatment of adult patients with BRAF V600 mutation positive unresectable or metastatic melanoma has been evaluated in 3 studies (BRF113683 [BREAK-3], BRF113929 [BREAK-MB], and BRF113710 [BREAK-2]) including patients with BRAF V600E and/or V600K mutations.
Učinkovitost dabrafeniba za zdravljenje odraslih bolnikov z inoperabilnim ali metastatskim melanomom z mutacijo BRAF V600 so ocenili v treh študijah (BRF113683 [BREAK-3], BRF113929 [BREAK-MB] in BRF113710 [BREAK-2]), ki so vključevale bolnike, ki so imeli mutacije BRAF V600E in/ali V600K.
The efficacy of dapagliflozin was also assessed separately in a dedicated study of diabetic subjects with moderate renal impairment (252 subjects with mean eGFR 45 ml/min/1.73 m2).
Učinkovitost dapagliflozina so ločeno ocenili tudi v namenski študiji sladkornih bolnikov z zmerno okvaro ledvic (252 preiskovancev s povprečnim eGFR 45 ml/min/1,73 m2).
The efficacy of dasabuvir has not been established in patients with HCV genotypes other than genotype 1; Exviera should not be used for the treatment of patients infected with other genotypes than 1.
Učinkovitost dasabuvirja ni ugotovljena pri bolnikih z drugimi genotipi HCV razen genotipa 1; zdravilo Exviera se ne sme uporabljati za zdravljenje bolnikov, okuženih z drugimi genotipi kot z genotipom 1.
The efficacy of desloratadine tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age.
Učinkovitosti tablet desloratadina ni bila jasno dokazana v preskušanjih pri mladostnikih, starih od 12 do 17 let.
The efficacy of duloxetine at the recommended dose of 60 mg once a day was demonstrated in three out of three randomised, double- blind, placebo-controlled, fixed dose acute studies in adult outpatients with major depressive disorder.
Učinkovitost duloksetina v priporočenem odmerku 60 mg enkrat na dan so pokazali v treh od treh randomiziranih dvojno slepih s placebom kontroliranih akutnih preskušanjih z določenim odmerkom pri odraslih bolnikih z veliko depresivno motnjo, zdravljenih ambulantno.
The efficacy of Duloxetine Lilly 30-120 mg (flexible dosing) once a day in elderly patients (>65 years) with generalised anxiety disorder was evaluated in a study that demonstrated statistically significant improvement in the HAM-A total score for duloxetine treated patients compared to placebo treated patients.
Učinkovitost zdravila Duloxetine Lilly 30-120 mg (prilagodljivo odmerjanje) enkrat na dan pri starejših bolnikih (> 65 let) z generalizirano anksiozno motnjo je bila ocenjena v študiji, ki je pokazala statistično pomembno izboljšanje skupnega števila točk po lestvici HAM-A za bolnike, zdravljene z duloksetinom, v primerjavi z bolniki, ki so prejemali placebo.
The efficacy of Duloxetine Lilly at the recommended dose of 60 mg once a day was demonstrated in three out of three randomised, double-blind, placebo-controlled, fixed dose acute studies in adult outpatients with major depressive disorder.
Učinkovitost zdravila Duloxetine Lilly v priporočenem odmerku 60 mg enkrat na dan so pokazali v treh od treh randomiziranih dvojno slepih s placebom kontroliranih akutnih preskušanjih z določenim odmerkom pri odraslih bolnikih z veliko depresivno motnjo, zdravljenih ambulantno.
The efficacy of ECALTA has only been evaluated in a limited number of neutropenic patients (see section 5.1)
Učinkovitost zdravila ECALTA je bila ocenjena le pri omejenem številu bolnikov z nevtropenijo (glejte poglavje 5.1).
The efficacy of eculizumab treatment in paediatric PNH patients appears to be consistent with that observed in adult PNH patients enrolled in PNH pivotal Studies (C04-001 and C04-002) (Table 3 and 9).
Učinkovitost zdravljenja z ekulizumabom pri pediatričnih bolnikih s PNH se zdi skladna s tisto, ki so jo opazovali pri odraslih bolnikih s PNH, ki so bili vključeni v ključne študije PNH (C04-001 in C04-002) (preglednici 3 in 9).
The efficacy of Enbrel in patients with non-radiographic axial spondyloarthritis (nr-AxSpa) was assessed in a randomised, 12-week double-blind, placebo-controlled study.
Učinkovitost zdravila Enbrel so pri bolnikih z radiografsko nezaznavnim aksialnim spondilartritisom (nr-AxSpa) ocenili v randomizirani 12-tedenski, dvojno slepi, s placebom nadzorovani študiji.
The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by a sPGA score ≥ 3, involving ≥ 10% of the BSA, and PASI ≥ 12).
Učinkovitost zdravila Enbrel so ugotavljali v randomizirani, dvojno slepi, s placebom nadzorovani študiji pri 211 pediatričnih bolnikih, starih 4 do 17 let, z zmerno do hudo psoriazo v plakih (definirano z oceno sPGA ≥ 3, ki zajema ≥ 10 % telesne površine (BSA – Body Surface Area), in PASI ≥ 12).
The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA score ≥ 3, involving ≥ 10% of the BSA, and PASI ≥ 12).
Učinkovitost zdravila Enbrel so ugotavljali v randomizirani, dvojno slepi, s placebom nadzorovani študiji pri 211 pediatričnih bolnikih, starih 4 do 17 let, z zmerno do hudo psoriazo v plakih (definirano z oceno sPGA ≥ 3, ki zajema ≥ 10 % telesne površine (BSA – Body Surface Area), in PASI ≥ 12).
The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid arthritis (<3 years duration) who had never received treatment with methotrexate.
V randomizirani študiji, nadzorovani z zdravilno učinkovino, so s slepo radiografsko oceno kot primarnim opazovanim dogodkom primerjali učinkovitost zdravila Enbrel z učinkovitostjo metotreksata pri 632 odraslih bolnikih z aktivnim revmatoidnim artritisom (trajanje bolezni manj kot 3 leta), ki se pred tem nikoli niso zdravili z metotreksatom.
The efficacy of enzalutamide in patients who have previously received abiraterone acetate has not been studied.
Učinkovitost enzalutamida pri bolnikih, ki so predhodno prejemali abirateron acetat še ni raziskana.
The efficacy of Epclusa was evaluated in three Phase 3 studies in patients with genotype 1 to 6 HCV infection with or without compensated cirrhosis and one Phase 3 study in patients with genotype 1 to 6 HCV infection with decompensated cirrhosis, as summarised in Table 9.
Učinkovitost zdravila Epclusa so ocenili v treh študijah 3. faze pri bolnikih z okužbo s HCV genotipa od 1 do 6 s kompenzirano cirozo ali brez nje in v eni študiji 3. faze pri bolnikih z okužbo s HCV genotipa od 1 do 6 z dekompenzirano cirozo, kot je povzeto v preglednici 9.
The efficacy of Eperzan was evaluated in a 3-year randomised, double-blind, placebo-controlled, multicentre study (n = 296) in patients inadequately controlled on diet and exercise.
Učinkovitost zdravila Eperzan so ocenili v 3-letni randomizirani, dvojno slepi, s placebom kontrolirani multicentrični študiji (n = 296) bolnikov, nezadostno urejenih z dieto in telesno dejavnostjo.
The efficacy of Eperzan was evaluated in a 3-year, randomised (2:1), open-label, insulin glargine-controlled noninferiority study (n = 735).
Učinkovitost zdravila Eperzan so ocenili v 3-letni randomizirani (2:1), odprti, z insulinom glarginom kontrolirani študiji neinferiornosti (n = 735).
The efficacy of Eperzan was evaluated in a 3-year, randomised, double-blind, multicentre study (n = 299).
Učinkovitost zdravila Eperzan so ocenili v 3-letni randomizirani, dvojno slepi multicentrični študiji (n = 299).
The efficacy of Eperzan was evaluated in a 3-year, randomised, double-blind, multicentre study (n = 657).
Učinkovitost zdravila Eperzan so ocenili v 3-letni randomizirani, dvojno slepi multicentrični študiji (n = 657).
The efficacy of Eperzan was evaluated in a 3-year, randomised, double-blind, multicentre study (n = 999).
Učinkovitost zdravila Eperzan so ocenili v 3-letni randomizirani, dvojno slepi multicentrični študiji (n = 999).
The efficacy of Eperzan was evaluated in a randomised, double-blind, active-controlled 52-week study in 486 patients with mild, moderate, and severe renal impairment inadequately controlled on a current regimen of diet and exercise or other antidiabetic therapy.
Učinkovitost zdravila Eperzan so ocenili v randomizirani, dvojno slepi, z aktivno učinkovino kontrolirani 52-tedenski študiji pri 486 bolnikih z blago, zmerno in hudo okvaro ledvic, neustrezno urejenih s trenutno shemo diete in telesne dejavnosti ali drugega antidiabetičnega zdravljenja.
The efficacy of etanercept in patients with non-radiographic axial spondyloarthritis (nr-AxSpa) was assessed in a randomised, 12-week double-blind, placebo-controlled study.
Učinkovitost etanercepta so pri bolnikih z radiografsko nezaznavnim aksialnim spondilartritisom (nr- AxSpa) ocenili v randomizirani 12-tedenski, dvojno slepi, s placebom nadzorovani študiji.
The efficacy of etanercept was compared to methotrexate in a randomised, active-controlled study with blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid arthritis (< 3 years duration) who had never received treatment with methotrexate.
V randomizirani študiji, nadzorovani z zdravilno učinkovino, so s slepo radiografsko oceno kot primarnim opazovanim dogodkom primerjali učinkovitost etanercepta z učinkovitostjo metotreksata pri 632 odraslih bolnikih z aktivnim revmatoidnim artritisom (trajanje bolezni manj kot 3 leta), ki se pred tem nikoli niso zdravili z metotreksatom.
The efficacy of Exelon transdermal patches in patients with Alzheimer’s dementia has been demonstrated in a 24-week double-blind, placebo-controlled core study and its open-label extension phase and in a 48-week double-blind comparator study.
Učinkovitost transdermalnih obližev Exelon pri bolnikih z Alzheimerjevo demenco so dokazali v 24-tedenski dvojno slepi, s placebom kontrolirani osnovni študiji in njenem odprtem podaljšku ter v 48-tedenski dvojno slepi primerjalni študiji.
The efficacy of FORSTEO in men and women (N=428) receiving sustained systemic glucocorticoid therapy (equivalent to 5 mg or greater of prednisone for at least 3 months) was demonstrated in the 18- month primary phase of a 36 month, randomised, double-blind, comparator-controlled study (alendronate 10 mg/day).
Učinkovitost zdravila FORSTEO pri moških in ženskah (N=428), ki so prejemali podaljšano sistemsko glukokortikoidno terapijo (kar ustreza 5 mg ali več prednizona v najmanj 3 mesecih) so dokazali v 18-mesečni začetni fazi 36-mesečne, randomizirane, dvojno slepe, s primerjavo kontrolirane študije (alendronat 10 mg/dan).
The efficacy of Fortacin was demonstrated in two multi-centre, multinational, randomised, double-blind, placebo controlled studies, both followed by an open-label phase.
Učinkovitost zdravila Fortacin je bila dokazana v dveh multicentričnih, multinacionalnih, randomiziranih, dvojno slepih, s placebom kontroliranih študijah, ki jima je sledila odprta faza.
The efficacy of fosaprepitant was evaluated based on the primary and secondary endpoints listed in Table 2 and was shown to be superior to the control regimen with regard to complete response in the delayed and overall phases.
Učinkovitost fosaprepitanta je bila ocenjena na osnovi primarnih in sekundarnih opazovanih dogodkov, navedenih v Preglednici 2, in se je izkazala za boljšo od kontrolne sheme zdravljenja glede na popoln odziv v zapozneli in celotni fazi.
The efficacy of Gardasil 9 against CIN 2 and worse related to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 compared to qHPV vaccine was 94.4% (95% CI 78.8 ; 99.0) with 2/5,952 versus 36/5,947 cases.
Učinkovitost cepiva Gardasil 9 proti CIN 2 in hujšim, povezanim s tipi HPV 6, 11, 16, 18, 31, 33, 45, 52 in 58, je bila v primerjavi s qHPV cepivom 94,4 % (95 % IZ: 78,8; 99,0) s številom primerov 2/5.952 v primerjavi s 36/5.947.
The efficacy of Gardasil 9 against CIN 3 related to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 compared to qHPV vaccine was 100% (95% CI 46.3 ; 100.0) with 0/5,952 versus 8/5,947 cases.
Učinkovitost cepiva Gardasil 9 proti CIN 3, povezani s tipi HPV 6, 11, 16, 18, 31, 33, 45, 52 in 58, je bila v primerjavi s qHPV cepivom 100 % (95 % IZ: 46,3; 100,0) s številom primerov 0/5.952 v primerjavi z 8/5.947.
The efficacy of Gardasil 9 in 16- through 26-year-old women was assessed in an active comparator-controlled, double-blind, randomized clinical study (Protocol 001) that included a total of 14,204 women (Gardasil 9 = 7,099; qHPV vaccine = 7,105).
Učinkovitost cepiva Gardasil 9 pri ženskah, starih od 16 do 26 let, so ocenili v dvojno slepi, randomizirani klinični študiji (Protokol 001), nadzorovani s primerjalno učinkovino, v katero je bilo vključenih 14.204 žensk (Gardasil 9 = 7.099, qHPV cepivo = 7.105).
The efficacy of Gardasil in 16- through 26- year-old women was assessed in 4 placebo-controlled, double-blind, randomized Phase II and III clinical studies including a total of 20,541 women, who were enrolled and vaccinated without pre-screening for the presence of HPV infection.
Učinkovitost cepiva Gardasil pri ženskah, starih 16 do 26 let, je bila ovrednotena v 4-ih s placebom nadzorovanih, dvojno slepih, randomiziranih kliničnih študijah II. in III. faze, v katere je bilo vključenih skupno 20.541 žensk, ki so bile v študije vključene in cepljene brez predhodnega pregleda za prisotnost okužbe s HPV.
The efficacy of Gardasil in 24- through 45-year-old women was assessed in 1 placebo-controlled, double-blind, randomized Phase III clinical study (Protocol 019, FUTURE III) including a total of 3,817 women, who were enrolled and vaccinated without pre-screening for the presence of HPV infection.
Učinkovitost cepiva Gardasil pri ženskah, starih 24 do 45 let, je bila ovrednotena v 1 s placebom nadzorovani, dvojno slepi, randomizirani klinični študiji III. faze (Protokol 019, FUTURE III), v katero je bilo vključenih 3.817 žensk, ki so bile v študijo vključene in cepljene brez predhodnega pregleda za prisotnost okužbe s HPV.
The efficacy of Gilenya has been demonstrated in two studies which evaluated once-daily doses of fingolimod 0.5 mg and 1.25 mg in patients with relapsing-remitting multiple sclerosis (RRMS).
Učinkovitost zdravila Gilenya pri bolnikih z recidivno remitentno multiplo sklerozo (RRMS) so dokazali v dveh študijah, v katerih so vrednotili odmerjanje 0,5 mg in 1,25 mg fingolimoda enkrat na dan.
The efficacy of glycerol phenylbutyrate in paediatric patients 2 months to 17 years of age involving deficiencies of OTC, ASS, ASL, and ARG was evaluated in 2 fixed sequence, open-label, sodium phenylbutyrate to equivalent dosing of glycerol phenylbutyrate switchover studies (Studies 3 and 4).
Učinkovitost glicerol fenilbutirata pri pediatričnih bolnikih, starih od 2 mesecev do 17 let z okvarami OTC, ASS, ASL in ARG so ocenjevali v dveh odprtih študijah prehoda s fiksnim zaporedjem, ki sta primerjali natrijev fenilbutirat z enakovrednimi odmerki glicerol fenilbutirata (Študija 3 in 4).
The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of EMEND.
Med jemanjem in 28 dni po koncu jemanja zdravila EMEND se lahko zmanjša učinkovitost hormonskih kontraceptivov.
The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of EMEND.
Med jemanjem zdravila EMEND in 28 dni po koncu jemanja se lahko zmanjša učinkovitost hormonskih kontraceptivov.
The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of fosaprepitant.
Med uporabo in še 28 dni po koncu uporabe fosaprepitanta se lahko zmanjša učinkovitost hormonskih kontraceptivov.
The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of fosaprepitant.
Med zdravljenjem s fosaprepitantom in še 28 dni po koncu zdravljenja s fosaprepitantom je učinkovitost hormonskih kontraceptivov lahko manjša.
The efficacy of hormonal contraceptives may be reduced if co-administered with olaparib (see also sections 4.4 and 4.6).
Učinkovitost hormonskih kontraceptivov se lahko zmanjša, če so uporabljeni sočasno z olaparibom (glejte tudi poglavji 4.4 in 4.6).
The efficacy of Humira was assessed in a randomised, double-blind, controlled study of 114 paediatric patients from 4 years of age with severe chronic plaque psoriasis (as defined by a PGA ≥ 4 or > 20% BSA involvement or > 10% BSA involvement with very thick lesions or PASI ≥ 20 or ≥ 10 with clinically relevant facial, genital, or hand/ foot involvement) who were inadequately controlled with topical therapy and heliotherapy or phototherapy.
Varnost in učinkovitost zdravila Humira so v randomiziranih, dvojno slepih študijah raziskali pri odraslih bolnikih s kronično psoriazo v plakih (zajete  10% telesne površine ter indeksom obsežnosti in izrazitosti psoriaze (PASI – Psoriasis Area and Severity Index)  12 ali  10), ki so bili kandidati za sistemsko zdravljenje ali fototerapijo.
The efficacy of Ilaris for the treatment of active SJIA was assessed in two pivotal studies (G2305 and G2301).
Učinkovitost zdravila Ilaris pri zdravljenju aktivnega SJIA so ocenjevali v dveh ključnih študijah (G2305 in G2301).
The efficacy of Ilaris for the treatment of acute gouty arthritis attacks was demonstrated in two multicentre, randomised, double-blind, active-controlled studies in patients with frequent gouty arthritis (≥ 3 attacks in the previous 12 months) unable to use NSAIDs or colchicine (due to contraindication, intolerance or lack of efficacy).
Učinkovitost zdravila Ilaris pri zdravljenju akutnih napadov uričnega artritisa so dokazali v dveh multicentričnih, randomiziranih, dvojno slepih, aktivno kontroliranih študijah z bolniki, ki so imeli pogoste napade uričnega artritisa (3 ali več napade v predhodnih 12 mesecih) in niso mogli uporabljati nesteroidnih protivnetnih zdravil ali kolhicina (zaradi kontraindikacij, neprenašanja ali nezadostnega učinka).
The efficacy of Improvac was studied in numerous laboratory and field studies.
Učinkovitost zdravila Improvac so raziskovali v številnih laboratorijskih in terenskih študijah.
The efficacy of InductOs was demonstrated in a multinational, randomized, controlled, single-blind study of 450 patients (age range 18 to 87 years; 81% male) with open tibial shaft fractures requiring surgical management.
Učinkovitost zdravila InductOs je bila dokazana v multinacionalni, randomizirani, kontrolirani, enojno slepi študiji, v katero je bilo vključenih 450 bolnikov (razpon starosti od 18 – 87 let; 81 % moških) z odprtim zlomom golenice, zaradi katerega je bila potrebna kirurška obravnava.
The efficacy of Intrinsa is reduced if your estrogen therapy is of a certain type (‘conjugated equine estrogens’).
Učinkovitost zdravila Intrinsa se zmanjša, če se zdravite z določeno vrsto estrogenov (‘konjugirani konjski estrogeni’).
The efficacy of INVANZ in the treatment of community acquired pneumonia due to penicillin- resistant Streptococcus pneumoniae has not been established.
Učinkovitost zdravila INVANZ pri zdravljenju zunajbolnišnične pljučnice, ki jo povzroča na penicilin odporna bakterija Streptococcus pneumoniae, ni bila dokazana.
The efficacy of ipilimumab for women above 50 years of age is therefore uncertain.
Pri bolnicah, starejših od 50 let, je učinkovitost ipilimumaba tako negotova.
The efficacy of JETREA was demonstrated in 2 multicentre, randomised, double-masked, placebo-controlled, 6-month studies in patients with VMT.
Učinkovitost zdravila JETREA je bila dokazana v 2 multicentričnih, randomiziranih, dvojno slepih, s placebom kontroliranih, 6-mesečnih študijah pri bolnikih z vitreomakularno trakcijo.